While the number of men on testosterone therapy has increased over the years, there has been little consensus to help providers determine who, exactly, should have it.  A panel of experts discussed this issue in a recent Journal of Sexual Medicine article.  

Dr. Abraham Morgentaler of Men’s Health Boston, Beth Israel Deaconess Medical Center, and Harvard Medical School, led the forum, which began in a post-graduate course called “Who is a candidate for testosterone therapy?” given at the 2012 World Meeting on Sexual Medicine in Chicago.

Dr. Mario Maggi (Sexual Medicine & Andrology, University of Florence, Italy), Dr. Mohit Khera (Baylor College of Medicine, Houston, Texas, USA), and Dr. Michael Zitzmann (Centre of Reproductive Medicine and Andrology/Clinical Andrology, University Clinics, Muenster, Germany) were the other panelists.

The experts gave their insights on a number of topics, including the symptoms, signs, and blood tests used to determine if testosterone therapy is appropriate. 

They also discussed the ways they monitored men on testosterone therapy in their practices and their thoughts on recent studies showing increased cardiovascular risk.

Please click here to see more details on this discussion.

For a limited time, ISSM members may publish in Sexual Medicine, the ISSM's open access journal, for $100.

This subsidy applies to the next 20 papers accepted for publication in Sexual Medicine authored by ISSM members. For eligible papers, ISSM members pay a special discounted rate of $100 (regularly $500). 

This offer is available to ISSM members only. Please click here to submit your manuscript. More information about publishing in Sexual Medicine may be found here. 

Further details about this program are available here.